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Abstract
Background: We have recently reported successful treatment of patients with chronic pain
syndromes using human pooled intravenous immunoglobulin (IVIG) in a prospective, open-label
cohort study. A randomised, placebo controlled, double blinded study is needed to confirm these
results. We chose to study patients with carbamazepine resistant primary Trigeminal Neuralgia
(rpTN), as these had responded particularly well to IVIG.
A protocol involving the use of IVIG in rpTN is complex for three reasons: 1. The effect of IVIG
does not follow simple dose-response rules; 2. The response pattern of patients to IVIG was
variable and ranged between no effect at all and pain free remission between two weeks and >1
year; 3. TN is characterized by extremely severe pain, for which operative intervention is (if
temporarily) helpful in most patients.
Design: A placebo controlled, parallel, add-on model was developed and the primary outcome
variable defined as the length of time during which patients remain in the study. Study groups are
compared using Kaplan-Maier survival analysis. Patients record their response to treatment
("severe, moderate, slight, no pain"). The study coordinator monitors pain diaries. Severe or
moderate pain of three days duration will result in termination of the study for that patient.
Conclusions: This study design utilizes a method of survival analysis and is novel in chronic pain
research. It allows for both early departure from the study and voluntary crossover upon non-
response. It may be applicable to the analysis of IVIG efficacy in other chronic pain syndromes.
Background
Patients who are suffering from primary trigeminal neu-
ralgia (pTN) and who have insufficient benefit from med-
ical therapy are frequently referred for operative
(microvascular decompression), or neuroablative inter-
vention. Although initial success rates from both methods
are high, they are associated with postoperative morbidity
[1]. In addition a significant proportion of patients
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experience return of their pain up to several years follow-
ing these procedures [2].
Patients with TN typically have "sharp, agonizing electric-
shock-like stabs or pain felt superficially in the skin or
buccal mucosa, triggered by light mechanical contact from
a more or less restricted site, usually of brief duration – a
few seconds (but reportedly occasionally up to 1–2 min-
utes) and followed by a refractory period of up to a few
minutes. Paroxysms may occur at intervals or many times
daily or, in rare instances, succeed one another almost
continuously "[3]. Pain intensity is mostly extremely se-
vere and is probably among the most intense pains expe-
rienced by humans. Therapy with carbamazepine does
alleviate symptoms in 60% of patients [4], but the treat-
ment effect can diminish over time. In addition side ef-
fects such as hyponatremia or difficulty with balance may
necessitate discontinuation of this medication [2].
We have treated patients with carbamazepine resistant
primary trigeminal neuralgia (rpTN) using human pooled
intravenous immunoglobulin (IVIG) in a prospective
multiple-dose, open-label cohort study [5]. We observed
pain free intervals of more than one year duration in five
out of ten patients following a median of three treatment
cycles [6].
There is clinical evidence, recently reviewed by Latov et al.,
that IVIG will be effective in some neurological diseases
[7]. To date the evidence for a clinically meaningful IVIG
efficacy is strongest in Guillain-Barré Syndrome and
Chronic Inflammatory Demyelinating Polyneuropathy
[8]. However in some cases where there is a purported ef-
fect, trials were small and outcomes of dubious relevance.
Moreover, methodologically sound trials were often less
positive. For instance, though IVIG is considered to be
possibly effective in multiple sclerosis, sound studies
showed no difference from placebo in reversal of persist-
ent visual loss [9] or established weakness [10]. The ben-
efits we found in an open, uncontrolled study [5,6] might
have been skewed by the many biases known to be asso-
ciated with this study-type and this therefore needs further
confirmation using a placebo controlled double blinded
trial design.
Challenges for the design of a prospective study include a
variable response pattern to IVIG treatment observed in
patients [5]. In the preliminary study some patients noted
no effect at all, while in patients with a favourable re-
sponse the pain relief observed was found to last between
two weeks and more than one year following a single dose
of IVIG. In some patients cumulative benefit was observed
with repeated administration of IVIG. Furthermore a 20%
response to placebo has been seen in randomised control-
led trials in TN [4].
Here we describe a study-design for a prospective, ran-
domised, double blinded study to evaluate the effect of
IVIG in rpTN. The study-hypothesis is that IVIG is more ef-
fective than placebo in relieving pain from rpTN. Because
of the severity of the pain and the fact that an invasive pro-
cedure is known to be effective, participants with no ben-
efit from IVIG would be allowed to leave the study and
undergo surgical treatment.
Design
Diagnosis and inclusion criteria
The study has a randomised, double-blind, placebo-con-
trolled, parallel, add-on design in a multicenter, outpa-
tient-based context. Major criteria for a study to be valid
are described below. Diagnosis of TN will be made ac-
cording to International Association for the Study of Pain
(IASP) criteria, as described above [3] with one exception:
we and others [11] have observed that some patients have
additional non dominant, continuous pain in the affected
area. Although not specifically mentioned in the IASP cri-
teria, these patients will be included. Patients will be eligi-
ble if they have been treated with carbamazepine with
insufficient pain relief (see below) or intolerable adverse
effects. Unsatisfactory results from treatments with other
anticonvulsive drugs [e.g. Lamotrigine, Gabapentin,
[12,13]] will be noted. Pre-treatment with these drugs is
not essential for study entry. We will include both patients
with rpTN who have not yet undergone an invasive proce-
dure (IP) and patients with no more than temporary ben-
efit following an IP. General inclusion/exclusion criteria
are listed in Table 1.
Enrolment
All patients considered candidates for this study will be
given a pain diary containing a daily categorical verbal
pain intensity scale (VPIS). A pain intensity scale with
items severe/moderate/slight/no pain [14] will be used.
Each patient will be asked to note in the evening his/her
average 24 h pain intensity using this scale for seven days.
In addition the number of bursts of pain (i.e. not individ-
ual stabs of pain but paroxysms of pain) and their strength
will be noted using an 11-point numeric rating scale. For
enrolment pain must be rated severe or moderate every-
day, and on at least five days severe. In addition more than
35 pain paroxysms must be documented during this peri-
od. If these criteria are fulfilled, this will be judged as in-
sufficient pain relief from established medication.
Patients with significant pain relief, but intolerable ad-
verse events with carbamazepine treatment may be in-
cluded if they have stopped taking carbamazepine, or
reduced its intake to a dose where adverse events are tol-
erable. The entrance criterion of insufficient pain relief
must then be fulfilled.BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/1
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Infection
We have previously noted an almost incessant return of
pain in a large proportion of patients with infection (e.g.
flu or cold) who had initially experienced pain relief fol-
lowing IVIG treatment. Therefore, the onset and duration
of infection will be noted in all patients and data will later
be stratified according to the rate of infection between the
groups. Enrolment into the study will be deferred for as
long as infection is present.
Blood samples
The mechanism of action of IVIG has not been elucidated
with certainty in any of the disorders, where it currently
indicated. Possible mechanisms in TN include the remov-
al of perineural proinflammatory cytokines [15] or the re-
moval of pathological serum antibodies [16]. All patients
will be requested to give blood for further analysis before
and following IVIG treatment. 40 ml of blood will be tak-
en at the start of the study, 2 weeks following treatment,
upon termination/completion of the main study and fol-
lowing the crossover period, if applicable. Serum will be
analysed for total IgA (see Table 1) and routine blood
chemical values and the remaining will be stored frozen at
-20C for later analysis of serum-cytokines and serum anti-
bodies. Peripheral blood cells will be frozen in liquid ni-
trogen for later cellular studies.
Allocation and blinding
Patients qualifying for enrolment who give written in-
formed consent after explanation of risks and potential
benefits will be allocated a number by the study-coordina-
tor. A computer at a central pharmacy will generate a ran-
domisation schedule and allocation of the active drug or
placebo to this number: allocation of patients to treat-
ment schedules will be concealed from investigators.
Study drugs for a particular number will be sent on de-
mand directly from the pharmacy to the pharmacy at the
peripheral study site. Blinding will be achieved at the pe-
ripheral pharmacy by wrapping the infusion bottle in alu-
minium foil and by wrapping the giving set in an opaque
foil. Normal saline will be used as placebo. All patients re-
ceive either 30 g of IVIG, divided into three applications
of 10 g (solubilized in 250 ml sterile water) each and giv-
en on alternate days (= one treatment cycle, TC), or place-
bo (Figure 1). The randomisation code will not be broken
until all patients have completed a 28 day study period
and a 28 day crossover period, if applicable.
Contact between patients will be discouraged. All patients
will receive the following information at enrolment:
1. Both IVIG and placebo may cause an initial pain in-
crease (see below) of up to 4 days duration with no pre-
dictive value to the ultimate treatment outcome.
2. Both IVIG and placebo may or may not reduce the pain
experienced and both may cause similar adverse events.
3. Pain relief may last as little as a few days, or as long as
a month, or even longer in some cases.
4. The study may be left at any time if treatment appears
insufficient.
Management of adverse events
Patients will be informed about possible adverse events
upon enrolment. The study coordinator must be contact-
ed should adverse events be observed. As this study will be
outpatient based, an observational period at the treatment
centre of one hour following the first administration and
30 minutes following consecutive administrations will be
required.
Pain and quality of life assessment
The study period ends 28 days after the first application of
IVIG. From the beginning of the study the 24 h average
pain intensity will be noted once daily using the same cat-
egorical rating scale as described above. In addition a
standard seven point Patient Global Impression of
Change Scale (PGIC, [17]) with the following items:
much worse/ minimally worse/ no change/ minimally im-
proved/ much improved/ very much improved will be
noted along with any adverse events experienced. This im-
pression of change wilI be referenced to the average status
in the week preceding drug administration. Finally the
number of paroxysms (see above) and their average
strength will be noted using a 24 hourly numeric rating
scale diary.
The Medical Outcomes Study 36-Item Short Form (SF-
36), Dartmouth Primary Care Cooperative Information
Project (COOP/WONCA) – Charts for adults, and the Per-
ceived Adjustment to Chronic Illness Scale (PACIS) [18–
Table 1: General inclusion and exclusion criteria
Inclusion criteria
Primary idiopathic trigeminal neuralgia
Age over 18
Insufficient benefit from carbamazepine therapy
Exclusion criteria
Serum IgA less than half normal value
Pregnancy or breastfeeding mothers
Progressive renal failure
Bedridden patients
Any disorder requiring treatment with IVIGB
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Figure 1
Time flow diagram of the study algorithm. All patients are assessed for 7 days in a recruitment period before commencement of the main study. They receive IVIG or 
Placebo on alternating days (day 1, 3, 5). Subsequently, a three-day period without monitoring is implemented because transitional pain increase has been noted in 
some patients, with no correlation with the ultimate efficacy of IVIG. Diary entries will be reviewed from day 9 onward. The main study ends at day 28. Crossover 
(upper half of diagram): all patients who leave the main study before 28 days will be offered crossover to the alternative treatment arm. Time points (day 1 C, 3 C, 5 
C, etc.) are similar to those in the main study. Patients are being offered surgery if they have insufficient pain relief: either upon leaving the main study (as an alternative 
to crossover), or following crossover treatment. The treatment allocations will be unblinded when all patients have completed the study. Plac: Placebo
Main study: D a y1D a y5 D a y9 D a y2 8=m a x i m a ll e n g t ho fm a i ns t u d y
IVIG/
Plac.
Recruit-
ment:
Assessment
if suitable or
not suitable
Review of pain diaries at regular
intervals starting with day 9. Decision
on continuation or stop of participation
in main study for each patient
depending on pain experienced
time
IVIG/
Plac.
Patients with insufficient benefit may decide whether
they want to cross over to the other treatment arm or
undergo surgery
Crossover (C):
Day 1C Day 5C Day 9C
time
Patients with insufficient benefit from IVIG therapy
may decide to undergo surgery
Patients who benefited from treatment may decide
to apply for further treatment with IVIG on the basis
of guess
Day 28 C = maximal length
of crossover
Start
Review of pain diaries at regular intervals
starting with day 9C. Decision on
continuation or stop of participation in
crossover study for each patient
depending on pain experiencedBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/1
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20] will be assessed in each patient at the beginning, two
weeks after the last IVIG application and upon leaving the
study (SF-36: only relevant questions at the last two time-
points, questions will be asked with relation to the "past
two", not "past four" weeks).
Concomitant medication
Doses of pain related drugs given before entry into this
study remain unchanged. However, upon discussion with
the study coordinator the dosage of pain related drugs
may be reduced: it was noted in the above mentioned pre-
liminary study that effective IVIG administration can re-
sult in a relative overdosing of concomitant pain related
drugs [6]. Reduction of a concomitant carbamazepine
dose will be compared between the groups and serves as a
secondary outcome parameter (Table 2).
Crossover and continuation of treatment
All patients will be offered crossover to the other treat-
ment upon termination of the main study. For those pa-
tients who decide to crossover, same criteria apply as
noted above. This "add on study" period ends 28 days fol-
lowing the administration of crossover medication.
Patients who wish continuation of their treatment after
the completion of the study because they experience a
beneficial effect following treatment and prefer this to an
operative procedure will be offered administrative help on
the basis of guess [21]. Administrative help will be provid-
ed by a health care professional not otherwise involveld in
the study, and results of further treatments will be con-
cealed from those health care workers involved in the
study until the code is broken. The study coordinator to-
gether with the patient will write an application to the ap-
propriate health insurance where the patient is insured.
For this it will be assumed that the effective treatment was
IVIG. Funding from other sources is ensured in such cases
where health insurances decline payment.
Follow up
All patients will be followed for a period of three years
from beginning of the study. They will be asked to note
treatments sought for TN during this period and to judge
treatment outcome using the above described categorical
pain relief scale. Long-term efficacy of IVIG treatment will
be researched. In addition a cost analysis will be per-
formed at the end of this period and treatment regiments
based on IVIG will be compared with operative and other
treatments.
Table 2: Secondary outcome parameters.
Variable Groups compared Scale Time period of 
evaluation
Time compared with
Improvement A PGIC α Week preceding treatment
Reduction in 
carbamazepine
A Fraction of patients with a reduc-
tion of dose; absolute reduction of 
dose
α As above
Pain A 11-point numeric rating scale α As above
Pain A Categorical verbal pain scale α As above
Pain A Average number of attacks α As above
Number of patients to 
cross over
A Fraction of patients enrolled in 
crossover period
At crossover -
Time in study B Number of days Crossover period Main study period
Improvement B PGIC α Same time periods post 
crossover, as judged against 
the week preceding 
treatment.
Pain B 11-point numeric rating scale α Same time periods post 
crossover
Pain B Categorical verbal pain scale α As above
Pain B Average number of paroxysms α As above
Quality of life A COOP/WONCA charts, SF-36 β -
Quality of life B PACIS, COOP/WONCA charts, 
SF-36
β PACIS: immediately before 
first treatment
A: Patients with placebo and patients with IVIG, B: Patients post crossover and same patients before crossover, α: Average of values from study day 
13–19 and average of values during 7 days before termination/ completion of study, β: First two weeks following (main or crossover) treatment and 
last two weeks before the end of (main or crossover) study for a particular patient, PACIS: one time point measurement at day 14 following treat-
ment and at the day of the end of (main or crossover) study. PGIC: Patient Global Impression of Change Scale [17]; SF-36: Medical Outcomes Study 
36-Item Short Form [18]; COOP/WONCA: Dartmouth Primary Care Cooperative Information Project charts for adults [19]; PACIS: Perceived 
Adjustment to Chronic Illness Scale [20].BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/1
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Primary outcome variable
The study coordinator will check all pain diaries at regular
intervals. This monitoring period will start four days after
the administration of the last dose of IVIG (= on the 9th
study day). A three-day period without monitoring is im-
plemented because transitional pain increase has been
noted in some patients following IVIG administration [5].
In our preliminary, observational study an initial pain in-
crease had no correlation with the ultimate efficacy of
IVIG. The primary outcome variable is defined as the
length of time patients remain in the study. The length of
time in which a patient remains in the study will be decid-
ed upon in two ways: the study-coordinator will terminate
the study for a patient if, with begin from day 10 the aver-
age pain intensity is noted as severe on three consecutive
days or if the average pain intensity is noted as moderate
and less than "much improved" in the 'impression of
change' scale).
In addition, patients can terminate the study at any time.
Reasons for termination will be noted. In such cases
where patients would not formally withdraw, but undergo
an operative procedure or start a new, pain related medi-
cation, the time of the new intervention is noted as the
time of study termination. Patients, which prematurely
terminate the study for other than the above mentioned
reasons will be included into an intention to treat
analysis.
Secondary outcome variables are listed in Table 2
Sample size calculation and statistical analysis
All patients and controls (minus dropouts) will remain in
the study for at least 11 days (Figure 1). In the remaining
17 study days, it was assumed, that patients treated with
the study drug will remain in the study for a median of 10
days from day 12, while patients receiving placebo will re-
main for a median of 3 days. A sample size calculation was
performed, based on the log-rank test. We found 80%
power to detect a hazard value of 3.3 or greater acceptable
and assumed a 25% dropout in both groups. We found
that 32 subjects needed to be enrolled in each treatment
arm. An intention to treat analysis was agreed to assign
dropouts at the study-end. An independent steering com-
mittee is scheduled to monitor outcome data at 28 days
following treatment of 32 patients. The committee will
discontinue the study, if no or less than 20% median sur-
vival advantage is observed in the drug versus placebo
group after stratification for dropouts in both groups. At
the end of the study, survival data will be analysed using
the log-rank test. This will be followed by Cox regression
analysis to explore the influence of patient characteristics
on IVIG response and to estimate hazard ratios.
Cost
The cost of this trial has yet to be established in detail.
Discussion
This study is designed to demonstrate whether the use of
IVIG in trigeminal neuralgia is of any clinical benefit.
Since most of these patients would normally proceed to
have neurosurgical procedures to alleviate their pain
when medical management had failed, the choice of pri-
mary outcome makes itself. It is whether surgery is avoid-
ed over a significant longer period of time in the group
treated with the study drug. This choice of outcome has
the advantage of being objective rather than subjective,
and of being of direct relevance both to patients and to
healthcare systems. Avoiding surgery has been used before
as the basis of systematic review [22] and economic anal-
ysis [23]. There is no alternative other than to perform a
randomised trial to test the hypothesis that IVIG is bene-
ficial in trigeminal neuralgia. Firstly, there is no obvious
or solid biological mechanism to explain the action of
IVIG in trigeminal neuralgia; we begin from the position
of perfect equipoise between it working and it not
working
An important issue is that even with no effect of IVIG pa-
tients should not come to harm. Apart from the fact that
they can leave the trial at any time if they feel it does them
no good, there are clear clinical stopping rules so that fail-
ure of treatment leads to trial of alternative therapy where-
by patients initially treated with saline have an
opportunity to try IVIG, or they have the option of pro-
ceeding to surgery.
Using this novel trial design in chronic pain implies, that
a potentially incremental benefit of IVIG with repeated
administration [5] cannot be assessed. Follow up data
over three years will be vital to gauge the economical
equation of IVIG versus surgery. It is important to note
that the IVIG dose employed in this trial is a fifth of that
in other (autoimmune) diseases and consequently that
the cost of treatment is likely to be lower than in these
disorders.
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